NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. SO WHAT: If you purchased Mereo ADSs during the Class Pe ...

Vancouver, British Columbia--(Newsfile Corp. - February 13, 2026) - Spark Energy Minerals Inc. (CSE: SPRK) (OTC Pink: SPARF) (FSE: 8PC) ("Spark" or the "Company") is pleased to report the final assay results from its maiden Reverse Circulation ("RC") drill program at the Arapaima Project in Brazil's Lithium Valley.All five maiden drill holes intersected broad rare earth ("REE") and gallium ("Ga") mineralization from surface to the bottom of the drilled interval. These results represent the complete assay d ...

NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group PLC (NASDAQ: MREO) (“Mereo” or the “Company”) inclusive on behalf of all persons and entities that purchased or otherwise acquired Mereo American Depositary Shares (“ADS’s”) between June 5, 2023 and December 26, 2025, both dates inclusive (the "Class Period"). Investors have until April 6, 2026, to seek appointments as lead plaintiff. PLEASE ...

New York, New York--(Newsfile Corp. - February 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026.SO WHAT: If you purchased Mereo ADSs during the Class Period you may be e ...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, (or 888.4-POMLAW), toll-f ...

Mereo BioPharma Group plc Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your Rights - MREO [Accessibility Statement] Skip NavigationNEW YORK, Feb. 12, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Mereo BioPharma Group plc (NASDAQ: MREO).Shareholders who purchased shares of MREO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment ...

LOS ANGELES, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mereo BioPharma Group plc, (“Mereo” or the "Company") (NASDAQ: MREO) investors of a class action on behalf of investors that bought securities between June 5, 2023 and December 26, 2025, inclusive (the “Class Period”). Mereo investors have until April 6, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal r ...

Core Viewpoint - Mereo BioPharma Group plc is facing a securities class action lawsuit due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [1][1]. Group 1: Legal Action and Deadlines - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in the class action [1]. - The lawsuit alleges that Mereo and its executives made false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs [1][1]. Group 2: Clinical Trial Results - Mereo announced on December 29, 2025, that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [1][1]. - Despite showing statistically significant improvements in bone mineral density on secondary endpoints, the failure to meet primary endpoints led to a negative market reaction [1]. Group 3: Stock Price Impact - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, representing an 87.64% decline, closing at $0.28 per share on December 29, 2025 [1][1].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Shares of Mereo BioPharma Group plc, covering the period from June 5, 2023, to December 26, 2025, due to alleged misleading statements regarding the company's clinical programs [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Mereo BioPharma made false and/or misleading statements and concealed material adverse facts about the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints of reducing annualized clinical fracture rates compared to control groups [5]. - Investors who purchased Mereo securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by April 6, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action has been filed against Mereo BioPharma Group plc for allegedly misleading investors regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which did not meet their primary endpoints [2][3] Group 1: Allegations and Misleading Information - The complaint alleges that Mereo BioPharma provided investors with overly optimistic statements about the expected results of the Phase 3 ORBIT and COSMIC studies, claiming confidence in setrusumab's ability to reduce annualized fracture rates [2] - It is claimed that while making these positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 studies, which ultimately did not achieve their primary endpoints [2] - The studies failed to show a reduction in annualized clinical fracture rates compared to placebo or bisphosphonate control groups, leading to artificially inflated prices for Mereo's American Depository Shares (ADS) [2] Group 2: Impact of the Announcement - On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC studies met their primary endpoint, resulting in a significant decline in the price of Mereo's ADS from $2.31 to $0.29, a drop of over 87.7% [3] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Mereo BioPharma, with a deadline to submit papers to serve as lead plaintiff by April 6, 2026 [4] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]